A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumours

Official Title

A Phase 2, Multicentre, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumours (DESTINY-PanTumour02)


This is an open-label, multi-centre, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumours.

This study will enroll 7 tumour-specific cohorts: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare tumours.

Study hypothesis: Trastuzumab deruxtecan will show meaningful clinical activity and a favourable risk benefit profile in selected HER2-expressing solid tumours.

Trial Description

Primary Outcome:

  • Objective Response Rate (ORR)
Secondary Outcome:
  • Duration of response (DoR)
  • Disease control rate (DCR)
  • Progression free survival (PFS)
  • Proportion of patients alive and progression-free at 6 months and 12 months
  • Overall survival (OS)
  • Proportion of patients alive at 6 and 12 months
  • Occurrence of adverse events (AEs) and serious adverse events (SAEs)
  • Pharmacokinetics (PK) assessed by serum concentration of T-DXd, total anti-HER2 antibody and MAAA-1181
  • The immunogenicity of T-DXd assessed by the presence of ADAs for T-DXd

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society